CompanyPurposeAnonymous Data SharedWhen collaboration Happened
EpigenomicsValidation of a new technique for improved sensitivity of lung cancer diagnosis in bronchial lavage samplesNone – data analysed in-house and results shared.2010 – 2012
Oxgford Gene TechnologiesInvestigating our ability to find useful DNA mutations routinely collected tumour histology samples (e.g. that might help target treatment or aid prognosis).None – data analysed in-house and results shared.2013 – 2015
Inivata LtdInvestigating new technology to find useful DNA mutations in blood samplesCancer diagnosis (type and stage)2015 – 2017
Biocrates life sciences agInvestigating the potential new technologies for cancer detection based on metabolites in bloodRisk profile and disease status

2016 – 2020
Janssen PharmaceuticalsGrant support for lung cancer research collaboration on early detection and prevention
Risk profile and disease status
None – data analysed in-house and results shared.2018- 2023
Roche DiagnosticsGrant support to investigate protein biomarkers for improved diagnosis of lung cancerNone – data analysed in-house and results shared.2020 – 2022
Company A*Collaboration investigating possible resistance to lung cancer and COPDAges at lung cancer and/or COPD, smoking duration/status, sex and outcome
2020 – 2026
Company T*Feasibility study for use of samples in epigenetics.
Age at lung cancer, histology, stage, sex and mutations2024 – 2025
Elypta ABValidation of GAGome risk marker for cancer early diagnosis. Sex, age at sample, cancer diagnosis, stage, histology, risk factors, comorbidities, outcome.2023 – 2026
* for reasons of confidentiality and commercial sensitivity, some names are withheld until study completion and publication